Cyclerion Therapeutics (CYCN) Free Cash Flow (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Free Cash Flow of -$264000.0 for Q3 2025, up 84.62% year-over-year from -$143000.0 in Q3 2024, and up 47.51% quarter-over-quarter from -$503000.0 in Q2 2025.
Cyclerion Therapeutics (CYCN) Free Cash Flow (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$264000.0 for Q3 2025.
- In Q3 2025, Free Cash Flow rose 84.62% year-over-year to -$264000.0; the TTM figure through Dec 2025 stood at -$1.7 million (up 59.96% YoY), while the FY2024 annual figure was -$4.3 million, up 79.4% from the prior year.
- Free Cash Flow for Q3 2025 stood at -$264000.0, up from -$503000.0 in the prior quarter.
- The five-year high for Free Cash Flow was $360000.0 in Q4 2024, with the low at -$14.4 million in Q1 2021.
- The 5-year median for Free Cash Flow is -$6.1 million (2023), against an average of -$5.4 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow tumbled 98.01% in 2022, then jumped 123.36% in 2024.
- Cyclerion Therapeutics' Free Cash Flow stood at -$8.3 million in 2021, then rose by 15.82% to -$7.0 million in 2022, then jumped by 77.83% to -$1.5 million in 2023, then surged by 123.36% to $360000.0 in 2024, then sank by 173.33% to -$264000.0 in 2025.
- Business Quant data shows CYCN's Free Cash Flow at -$264000.0 in Q3 2025, -$503000.0 in Q2 2025, and -$968000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -264,000.00 |
| Sep 30, 2025 | -264,000.00 |
| Jun 30, 2025 | -503,000.00 |
| Jun 30, 2025 | -503,000.00 |
| Mar 31, 2025 | -968,000.00 |
| Mar 31, 2025 | -968,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | -1.72 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | -1.11 Mn |
| Mar 31, 2024 | -1.87 Mn |
| Mar 31, 2024 | -1.87 Mn |
| Dec 31, 2023 | -1.54 Mn |
| Dec 31, 2023 | -1.54 Mn |
| Sep 30, 2023 | -6.90 Mn |
| Sep 30, 2023 | -6.90 Mn |
| Jun 30, 2023 | -6.46 Mn |
| Jun 30, 2023 | -6.46 Mn |